Tetraphase Pharmaceuticals Stock Price Down 7.8% Following Weak Earnings (TTPH)
Tetraphase Pharmaceuticals (NASDAQ:TTPH)’s share price dropped 7.8% during mid-day trading on Wednesday following a weaker than expected earnings announcement, Analyst Ratings Network reports. The company traded as low as $10.67 and last traded at $10.91, with a volume of 162,289 shares changing hands. The stock had previously closed at $11.83.
The company reported ($0.71) EPS for the quarter, missing the Thomson Reuters consensus estimate of ($0.54) by $0.17. The company had revenue of $1.30 million for the quarter, compared to the consensus estimate of $2.79 million.
A number of research firms have recently commented on TTPH. Analysts at Brean Capital initiated coverage on shares of Tetraphase Pharmaceuticals in a research note on Tuesday, July 8th. They set a “buy” rating and a $23.00 price target on the stock. Separately, analysts at TheStreet upgraded shares of Tetraphase Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Friday, June 20th. Finally, analysts at Gabelli initiated coverage on shares of Tetraphase Pharmaceuticals in a research note on Friday, June 20th. They set a “buy” rating on the stock. One analyst has rated the stock with a hold rating and nine have assigned a buy rating to the stock. Tetraphase Pharmaceuticals presently has an average rating of “Buy” and an average target price of $18.75.
The stock’s 50-day moving average is $11.64 and its 200-day moving average is $11.. The company’s market cap is $286.7 million.
Tetraphase Pharmaceuticals, Inc, incorporated on July 7, 2006, is a clinical stage biopharmaceutical company.
Receive News & Ratings for Tetraphase Pharmaceuticals Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tetraphase Pharmaceuticals Inc and related companies with Analyst Ratings Network's FREE daily email newsletter.